PLAT3 Antibody

PLAT Antibodies: Overview

PLAT (tissue-type plasminogen activator) is a serine protease critical for fibrinolysis, converting plasminogen to plasmin. Antibodies targeting PLAT are primarily used in research and diagnostics to study thrombotic and bleeding disorders .

Platelet-Targeted Antibodies: Clinical and Research Significance

Antibodies against platelet glycoproteins (e.g., GPIIb/IIIa, GPIb/IX) are implicated in immune thrombocytopenic purpura (ITP) and vaccine-induced thrombotic thrombocytopenia (VITT) .

Anti-GPIIb/IIIa Autoantibodies in ITP

• Binding Specificity: Conformational epitopes on GPIIb/IIIa requiring divalent cations (e.g., Ca²⁺/Mg²⁺) .

• Clinical Impact:

  • Found in 62–68% of pediatric ITP cases, but not predictive of chronicity .

  • Mediate platelet destruction via Fcγ receptor-mediated phagocytosis .

VITT Antibodies

• Mechanism: Anti-PF4 (platelet factor 4) antibodies form immune complexes, activating platelets via FcγRIIA .

• Key Findings:

  • Heparin Independence: Unlike HIT (heparin-induced thrombocytopenia), VITT antibodies activate platelets without heparin .

  • Binding Kinetics: Higher affinity for PF4 compared to HIT antibodies (SPR analysis: KD < 0.4 nM) .

Platelet Antibody Profiling

Functional Assays

• Aggregation Studies: Anti-prothrombin antibodies induce platelet activation via FcγRIIA and Syk/Src signaling .

• Inhibitor Testing: Eptifibatide (αIIbβ3 blocker) and IV.3 (FcγRIIA blocker) suppress antibody-mediated activation .

Research Trends and Challenges

• Epitope Mapping: Alanine scanning and SPR identify critical residues for antibody binding (e.g., hANKRD1 mAbs) .

• Antibody Validation: Only 41–63% of commercial antibodies show specificity in cell-line Western blots .

Data Gaps and Limitations

• No studies directly address "PLAT3" as a target.

• PLAT antibodies are distinct from platelet glycoprotein antibodies; conflating these may lead to misinterpretation.